{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:47:57Z","timestamp":1789548477188,"version":"build-2803163510"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Education, University and Research"},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022P5LPHS"],"award-info":[{"award-number":["2022P5LPHS"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NextGenerationEU initiative and PNRR MUR"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bioorg.2025.108693","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T19:05:26Z","timestamp":1750100726000},"page":"108693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Peroxisome proliferator-activated receptor antagonists as emerging therapeutics in cancer treatment"],"prefix":"10.1016","volume":"163","author":[{"given":"Snehal","family":"Misal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay M.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Ramaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lavecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108693_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.108693_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.737776","article-title":"PPAR-\u03b3 modulators as current and potential cancer treatments","volume":"11","author":"Chi","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2017.12.003","article-title":"Cancer-associated fibroblasts in tumor microenvironment\u2013accomplices in tumor malignancy","volume":"343","author":"Liao","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrc.2017.102","article-title":"An evolutionary perspective on field cancerization","volume":"18","author":"Curtius","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108693_bb0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12943-019-0961-y","article-title":"Reactive oxygen species: a volatile driver of field cancerization and metastasis","volume":"18","author":"Liao","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2025.108693_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.impact.2020.100253","article-title":"Smart nanocarriers for cancer treatment: clinical impact and safety","volume":"20","author":"Liao","year":"2020","journal-title":"NanoImpact"},{"key":"10.1016\/j.bioorg.2025.108693_bb0035","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108693_bb0040","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.clinthera.2016.03.026","article-title":"Current challenges in cancer treatment","volume":"38","author":"Zugazagoitia","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bioorg.2025.108693_bb0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jconrel.2021.05.042","article-title":"Magnetic nanoparticles for cancer theranostics: advances and prospects","volume":"335","author":"Li","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioorg.2025.108693_bb0050","article-title":"Diagnostic and prognostic value of circulating CircRNAs in cancer","volume":"8","author":"Wang","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.bioorg.2025.108693_bb0055","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/cells9051133","article-title":"PPAR beta\/delta and the hallmarks of cancer","volume":"9","author":"Wagner","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.108693_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.599995","article-title":"PPAR-\u03b1 modulators as current and potential cancer treatments","volume":"11","author":"Tan","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0065","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.3390\/cells11152432","article-title":"Peroxisome proliferator-activated receptors and the hallmarks of cancer","volume":"11","author":"Wagner","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.108693_bb0070","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0092-8674(92)90031-7","article-title":"Control of the peroxisomal \u03b2-oxidation pathway by a novel family of nuclear hormone receptors","volume":"68","author":"Dreyer","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108693_bb0075","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108693_bb0080","first-page":"3344","article-title":"Ligand for peroxisome proliferator-activated receptor \u03b3 (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo","volume":"58","author":"Kubota","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0085","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10549-008-9944-1","article-title":"Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells","volume":"113","author":"Bonofiglio","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bioorg.2025.108693_bb0090","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bbalip.2007.02.004","article-title":"Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease","volume":"1771","author":"Michalik","year":"2007","journal-title":"Biochimica et Biophysica Acta (BBA)-Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.bioorg.2025.108693_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc3214","article-title":"The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention","volume":"12","author":"Peters","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108693_bb0100","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/713608372","article-title":"PPAR\u03b1 agonist-induced rodent tumors: modes of action and human relevance","volume":"33","author":"Klaunig","year":"2003","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0105","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41580-022-00486-7","article-title":"Transcriptional control of energy metabolism by nuclear receptors","volume":"23","author":"Scholtes","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154338","article-title":"The role of peroxisome proliferator-activated receptors (PPAR) in immune responses","volume":"114","author":"Christofides","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.bioorg.2025.108693_bb0115","doi-asserted-by":"crossref","first-page":"9223","DOI":"10.3390\/ijms22179223","article-title":"Structural biology-based exploration of subtype-selective agonists for peroxisome proliferator-activated receptors","volume":"22","author":"Miyachi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0125","series-title":"Encyclopedia of Toxicology","first-page":"815","article-title":"Peroxisome proliferators","author":"Jiang","year":"2014"},{"key":"10.1016\/j.bioorg.2025.108693_bb0130","series-title":"The Role of PPARs in Disease","author":"Wagner","year":"2020"},{"key":"10.1016\/j.bioorg.2025.108693_bb0135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nm1025","article-title":"PPARs and the complex journey to obesity","volume":"10","author":"Evans","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.108693_bb0140","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1172\/JCI27958","article-title":"Involvement of PPAR nuclear receptors in tissue injury and wound repair","volume":"116","author":"Michalik","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.108693_bb0145","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1097-2765(00)00026-5","article-title":"Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding","volume":"6","author":"Pissios","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2025.108693_bb0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nsb0196-87","article-title":"A canonical structure for the ligand-binding domain of nuclear receptors","volume":"3","author":"Wurtz","year":"1996","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0155","first-page":"287","article-title":"Different agonist-and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping","volume":"14","author":"Keidel","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phrs.2004.07.012","article-title":"An overview on biological mechanisms of PPARs","volume":"51","author":"Kota","year":"2005","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0165","doi-asserted-by":"crossref","first-page":"20230","DOI":"10.1074\/jbc.272.32.20230","article-title":"Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3): differential activity of PPAR\u03b31 and \u22122 isoforms and influence of insulin","volume":"272","author":"Werman","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108693_bb0170","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.bbalip.2016.09.003","article-title":"The effect of regulating molecules on the structure of the PPAR-RXR complex","volume":"1861","author":"Amber-Vitos","year":"2016","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"},{"key":"10.1016\/j.bioorg.2025.108693_bb0175","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0969-2126(01)00634-7","article-title":"Structure of the PPAR\u03b1 and -\u03b3 ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family","volume":"9","author":"Cronet","year":"2001","journal-title":"Structure"},{"key":"10.1016\/j.bioorg.2025.108693_bb0180","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1097-2765(00)80467-0","article-title":"Molecular recognition of fatty acids by peroxisome proliferator\u2013activated receptors","volume":"3","author":"Xu","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2025.108693_bb0185","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1097-2765(00)80448-7","article-title":"Asymmetry in the PPAR\u03b3\/RXR\u03b1 crystal structure reveals the molecular basis of heterodimerization among nuclear receptors","volume":"5","author":"Gampe","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2025.108693_bb0280","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/tox.22097","article-title":"AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-\u03baB pathway","volume":"31","author":"Tsai","year":"2016","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178995","article-title":"Effects of PPAR\u03b1 inhibition in head and neck paraganglioma cells","volume":"12","author":"Florio","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bioorg.2025.108693_bb0290","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejphar.2017.05.008","article-title":"In vitro and in vivo pharmacology of NXT629, a novel and selective PPAR\u03b1 antagonist","volume":"809","author":"Stebbins","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0295","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/jcp.25648","article-title":"PPAR\u03b1 antagonist AA452 triggers metabolic reprogramming and increases sensitivity to radiation therapy in human glioblastoma primary cells","volume":"232","author":"E. Benedetti, M. d'Angelo, A. Ammazzalorso, G.L. Gravina, C. Laezza, A. Antonosante, G. Panella, B. Cinque, L. Cristiano, A.C. Dhez, C. Astarita, R. Galzio, M.G. Cifone, R. Ippoliti, R. Amoroso, E. Di Cesare, A. Giordano, A. Cimini","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0300","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1021\/acsmedchemlett.9b00666","article-title":"Sulfonimide and amide derivatives as novel PPAR\u03b1 antagonists: synthesis, antiproliferative activity, and docking studies","volume":"11","author":"Ammazzalorso","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108693_bb0305","series-title":"Effects of MK886 on hepatic lipid metabolism in non-alcoholic fatty liver disease","author":"Du","year":"2022"},{"key":"10.1016\/j.bioorg.2025.108693_bb0310","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejmech.2017.07.019","article-title":"Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis","volume":"153","author":"G\u00fcr","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108693_bb0315","first-page":"1100","article-title":"First-in-human phase i trial of TPST-1120, an inhibitor of PPAR\u03b1, as monotherapy or in combination with nivolumab, in patients with advanced solid tumors, Cancer research","volume":"4","author":"Yarchoan","year":"2024","journal-title":"Communications"},{"key":"10.1016\/j.bioorg.2025.108693_bb0320","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4161\/cbt.8.13.8691","article-title":"A novel peroxisome proliferator-activated receptor delta antagonist, SR13904, has anti-proliferative activity in human cancer cells","volume":"8","author":"Zaveri","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bioorg.2025.108693_bb0325","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1158\/0008-5472.CAN-18-1790","article-title":"Pleiotropic effects of PPARD accelerate colorectal tumorigenesis, progression, and invasion","volume":"79","author":"Liu","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0330","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/emmm.201302666","article-title":"Src is activated by the nuclear receptor peroxisome proliferator-activated receptor \u03b2\/\u03b4 in ultraviolet radiation-induced skin cancer","volume":"6","author":"Montagner","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bioorg.2025.108693_bb0270","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1124\/mol.111.074039","article-title":"High-affinity peroxisome proliferator-activated receptor \u03b2\/\u03b4-specific ligands with pure antagonistic or inverse agonistic properties","volume":"80","author":"Naruhn","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0335","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1158\/0008-5472.CAN-13-0384","article-title":"Genetic ablation of the fatty acid\u2013binding protein FABP5 suppresses HER2-induced mammary tumorigenesis","volume":"73","author":"Levi","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0340","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/jm2017122","article-title":"(Z)-2-(2-Bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172): an orally bioavailable PPAR\u03b2\/\u03b4-selective ligand with inverse agonistic properties","volume":"55","author":"Lieber","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108693_bb0345","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1111\/j.1349-7006.2008.00904.x","article-title":"Inhibition of peroxisome proliferator-activated receptor \u03b3 activity suppresses pancreatic cancer cell motility","volume":"99","author":"Nakajima","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0350","first-page":"813","article-title":"The PPAR\u03b3 antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPAR\u03b3-dependent and -independent mechanisms","volume":"31","author":"Zaytseva","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0355","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1042\/bj3620573","article-title":"Bisphenol a diglycidyl ether induces apoptosis in tumour cells independently of peroxisome proliferator-activated receptor-\u03b3, in caspase-dependent and -independent manners","volume":"362","author":"Fehlberg","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2025.108693_bb0360","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/sj.bjp.0705973","article-title":"GW9662, a potent antagonist of PPAR\u03b3, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR\u03b3 agonist rosiglitazone, independently of PPAR\u03b3 activation","volume":"143","author":"Seargent","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0365","first-page":"1550","article-title":"A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor \u03b3","volume":"14","author":"Wang","year":"2000","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0370","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jsbmb.2011.01.019","article-title":"HL005\u2014a new selective PPAR\u03b3 antagonist specifically inhibits the proliferation of MCF-7","volume":"124","author":"Lu","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.693","article-title":"Identification of an irreversible PPAR\u03b3 antagonist with potent anticancer activity","volume":"8","author":"Peng","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.bioorg.2025.108693_bb0190","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/pro.3496","article-title":"The nuclear receptor superfamily: a structural perspective","volume":"27","author":"Weikum","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0195","doi-asserted-by":"crossref","first-page":"L15","DOI":"10.1016\/j.bpj.2009.11.029","article-title":"From induced fit to conformational selection: a continuum of binding mechanism controlled by the timescale of conformational transitions","volume":"98","author":"Zhou","year":"2010","journal-title":"Biophys. J."},{"key":"10.1016\/j.bioorg.2025.108693_bb0200","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1021\/acs.jcim.9b00360","article-title":"Ligand pathways in nuclear receptors","volume":"59","author":"Fischer","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.108693_bb0205","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.celrep.2016.09.060","article-title":"A mathematical model of the liver circadian clock linking feeding and fasting cycles to clock function","volume":"17","author":"Woller","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2025.108693_bb0210","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.3390\/ijms20205055","article-title":"Exploration and development of PPAR modulators in health and disease: an update of clinical evidence","volume":"20","author":"Cheng","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0215","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1038\/s41467-019-13768-0","article-title":"Definition of functionally and structurally distinct repressive states in the nuclear receptor PPAR\u03b3","volume":"10","author":"Heidari","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108693_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2020.1703952","article-title":"Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present)","volume":"30","author":"Takada","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2025.108693_bb0225","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1089\/ars.2008.2280","article-title":"PPARs and the cardiovascular system","volume":"11","author":"Hamblin","year":"2009","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bioorg.2025.108693_bb0230","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jsbmb.2010.06.012","article-title":"Metabolic impact of estrogen signalling through ERalpha and ERbeta","volume":"122","author":"Foryst-Ludwig","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0235","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","article-title":"The many faces of PPAR\u03b3","volume":"123","author":"Lehrke","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108693_bb0240","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.3748\/wjg.v29.i26.4136","article-title":"Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: focus on the adipose tissue, liver, and pancreas","volume":"29","author":"Souza-Tavares","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0245","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1152\/physrev.00025.2005","article-title":"Transcriptional regulation of metabolism","volume":"86","author":"Desvergne","year":"2006","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bioorg.2025.108693_bb0250","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bbalip.2007.02.013","article-title":"PPARs and molecular mechanisms of transrepression","volume":"1771","author":"Ricote","year":"2007","journal-title":"Biochimica et Biophysica Acta (BBA)-Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.bioorg.2025.108693_bb0255","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12272-015-0559-x","article-title":"The multifaceted factor peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) in metabolism, immunity, and cancer","volume":"38","author":"Kim","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0260","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/phrs.2001.0871","article-title":"PPARS, metabolic disease and atherosclerosis","volume":"44","author":"Fruchart","year":"2001","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0265","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4714914","article-title":"Impact of phytochemicals on PPAR receptors: implications for disease treatments","volume":"2022","author":"Enayati","year":"2022","journal-title":"PPAR Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0275","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/102737","article-title":"The role of PPARs in cancer","volume":"2008","author":"Tachibana","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1074911","article-title":"PPAR\u03b1: an emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0385","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/35013000","article-title":"Roles of PPARs in health and disease","volume":"405","author":"Kersten","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108693_bb0390","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/612089","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"2010","author":"Rakhshandehroo","year":"2010","journal-title":"PPAR Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0395","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1172\/JCI200420468","article-title":"PPAR\u03b1 governs glycerol metabolism","volume":"114","author":"Patsouris","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.108693_bb0400","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/271983","article-title":"Peroxisome proliferator-activated receptors and the heart: lessons from the past and future directions","volume":"2015","author":"Lee","year":"2015","journal-title":"PPAR Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0405","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/biology11050792","article-title":"PPAR alpha as a metabolic modulator of the liver: role in the pathogenesis of nonalcoholic steatohepatitis (NASH)","volume":"11","author":"Todisco","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.bioorg.2025.108693_bb0410","doi-asserted-by":"crossref","first-page":"10545","DOI":"10.3390\/ijms221910545","article-title":"The role of PPAR alpha in the modulation of innate immunity","volume":"22","author":"Grabacka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0415","doi-asserted-by":"crossref","first-page":"24484","DOI":"10.1074\/jbc.M202449200","article-title":"WY14, 643, a peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP\/F-1 mice","volume":"277","author":"Chou","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108693_bb0420","doi-asserted-by":"crossref","first-page":"16638","DOI":"10.1074\/jbc.275.22.16638","article-title":"Peroxisome proliferator-activated receptor \u03b1 activators improve insulin sensitivity and reduce adiposity","volume":"275","author":"Guerre-Millo","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108693_bb0425","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2337\/diabetes.50.2.411","article-title":"Peroxisome proliferator\u2014activated receptor (PPAR)-\u03b1 activation lowers muscle lipids and improves insulin sensitivity in high fat\u2014fed rats: comparison with PPAR-\u03b3 activation","volume":"50","author":"Ye","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.bioorg.2025.108693_bb0430","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bioorg.2025.108693_bb0435","first-page":"1","article-title":"Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-\u03baB pathway","volume":"14","author":"Li","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2025.108693_bb0440","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/leu.2010.117","article-title":"Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNF\u03b1\/NF-\u03baB signaling axis","volume":"24","author":"Zak","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2025.108693_bb0445","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/0008-5472.CAN-13-1928","article-title":"PPAR\u03b1 activation can help prevent and treat non\u2013small cell lung cancer","volume":"74","author":"Skrypnyk","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-9966-32-43","article-title":"Targeting 3-phosphoinositide-dependent protein kinase 1 by N-acetyl-cysteine through activation of peroxisome proliferators activated receptor alpha in human lung cancer cells, the role of p53 and p65","volume":"32","author":"Hann","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0455","doi-asserted-by":"crossref","first-page":"17685","DOI":"10.1074\/jbc.M701429200","article-title":"Peroxisomal proliferator-activated receptor-\u03b1-dependent inhibition of endothelial cell proliferation and tumorigenesis","volume":"282","author":"Pozzi","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108693_bb0460","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/cbf.1691","article-title":"Involvement of PPAR\u03b1 and PPAR\u03b3 in apoptosis and proliferation of human hepatocarcinoma HepG2 cells","volume":"28","author":"Maggiora","year":"2010","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.bioorg.2025.108693_bb0465","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2119\/molmed.2015.00139","article-title":"A selective novel peroxisome proliferator-activated receptor (PPAR)-\u03b1 antagonist induces apoptosis and inhibits proliferation of cll cells in vitro and in vivo","volume":"21","author":"Messmer","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.bioorg.2025.108693_bb0470","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/biomedicines9020127","article-title":"PPAR\u03b1-selective antagonist GW6471 inhibits cell growth in breast cancer stem cells inducing energy imbalance and metabolic stress","volume":"9","author":"Castelli","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2025.108693_bb0475","first-page":"E2563","article-title":"Structural basis for specific ligation of the peroxisome proliferator-activated receptor \u03b4","volume":"114","author":"Wu","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0480","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/415813a","article-title":"Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR \u03b1","volume":"415","author":"Xu","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108693_bb0485","first-page":"C890","article-title":"PPAR\u03b1 inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth, American journal of physiology-cell","volume":"308","author":"Abu Aboud","year":"2015","journal-title":"Physiology"},{"key":"10.1016\/j.bioorg.2025.108693_bb0490","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejmech.2012.10.019","article-title":"Fibrate-derived N-(methylsulfonyl)amides with antagonistic properties on PPAR\u03b1","volume":"58","author":"Ammazzalorso","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108693_bb0495","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/cbdd.13026","article-title":"Cytotoxic effect of a family of peroxisome proliferator-activated receptor antagonists in colorectal and pancreatic cancer cell lines","volume":"90","author":"Ammazzalorso","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2025.108693_bb0500","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1016\/j.bmcl.2011.06.028","article-title":"Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPAR\u03b1 antagonists","volume":"21","author":"Ammazzalorso","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108693_bb0505","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1042\/bj3560899","article-title":"Inhibition of peroxisome-proliferator-activated receptor (PPAR)\u03b1 by MK886","volume":"356","author":"Kehrer","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2025.108693_bb0510","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s12185-011-0954-0","article-title":"MK886 inhibits the proliferation of HL-60 leukemia cells by suppressing the expression of mPGES-1 and reducing prostaglandin E2 synthesis","volume":"94","author":"Li","year":"2011","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0515","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10787-017-0327-2","article-title":"PPAR\u03b1\/\u03b3 antagonists reverse the ameliorative effects of osthole on hepatic lipid metabolism and inflammatory response in steatohepatitic rats","volume":"26","author":"Zhao","year":"2018","journal-title":"Inflammopharmacol"},{"key":"10.1016\/j.bioorg.2025.108693_bb0520","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.bioorg.2025.108693_bb0525","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a Nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.bioorg.2025.108693_bb0530","author":"Stock"},{"key":"10.1016\/j.bioorg.2025.108693_bb0535","series-title":"Use of Fibrates and Cancer Risk: A Systematic Review and Meta-analysis of 17 Long-term Randomized Placebo-controlled Trials","author":"Bonovas","year":"2012"},{"key":"10.1016\/j.bioorg.2025.108693_bb0540","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00204-017-2094-7","article-title":"The PPAR\u03b1-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions","volume":"92","author":"Corton","year":"2018","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0545","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1074\/jbc.270.5.2367","article-title":"Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes: homology to peroxisome proliferator-activated receptors","volume":"270","author":"Amri","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108693_bb0550","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1006\/bbrc.1993.2302","article-title":"Identification of two mPPAR related receptors and evidence for the existence of five subfamily members","volume":"196","author":"Chen","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.108693_bb0555","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1073\/pnas.91.15.7355","article-title":"Differential expression and activation of a family of murine peroxisome proliferator-activated receptors","volume":"91","author":"Kliewer","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0560","first-page":"1634","article-title":"Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids","volume":"6","author":"Schmidt","year":"1992","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0565","doi-asserted-by":"crossref","first-page":"13416","DOI":"10.18632\/oncotarget.3826","article-title":"Deregulation of PPAR\u03b2\/\u03b4 target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment","volume":"6","author":"Schumann","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108693_bb0570","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1101\/gad.13.12.1561","article-title":"Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPAR\u03b4","volume":"13","author":"Lim","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.bioorg.2025.108693_bb0575","doi-asserted-by":"crossref","first-page":"13275","DOI":"10.1073\/pnas.97.24.13275","article-title":"Prostacyclin-mediated activation of peroxisome proliferator-activated receptor \u03b4 in colorectal cancer","volume":"97","author":"Gupta","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0580","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0585","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.3390\/ijms19072124","article-title":"PPARs and metabolic disorders associated with challenged adipose tissue plasticity","volume":"19","author":"Corrales","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0590","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/CIRCRESAHA.107.170233","article-title":"Peroxisome proliferator-activated receptor \u03b2\/\u03b4 goes vascular","volume":"102","author":"Bishop-Bailey","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0595","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3390\/cells8121623","article-title":"Vascular PPAR\u03b2\/\u03b4 promotes tumor angiogenesis and progression","volume":"8","author":"Wagner","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.108693_bb0600","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.cmet.2017.04.006","article-title":"PPAR\u03b4 promotes running endurance by preserving glucose","volume":"25","author":"Fan","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.bioorg.2025.108693_bb0605","first-page":"43","article-title":"Nutritional regulation and role of peroxisome proliferator-activated receptor \u03b4 in fatty acid catabolism in skeletal muscle, Biochimica et Biophysica acta (BBA) - molecular and cell biology of","volume":"1633","author":"Holst","year":"2003","journal-title":"Lipids"},{"key":"10.1016\/j.bioorg.2025.108693_bb0610","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1172\/JCI42127","article-title":"PPAR\u03b2\/\u03b4 affects pancreatic \u03b2 cell mass and insulin secretion in mice","volume":"122","author":"Iglesias","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.108693_bb0615","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41598-017-00889-z","article-title":"Intestinal PPAR\u03b4 protects against diet-induced obesity, insulin resistance and dyslipidemia","volume":"7","author":"Doktorova","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108693_bb0620","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1073\/pnas.0511253103","article-title":"PPAR\u03b4 regulates glucose metabolism and insulin sensitivity","volume":"103","author":"Lee","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0625","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cmet.2013.10.012","article-title":"Desnutrin\/ATGL activates PPAR\u03b4 to promote mitochondrial function for insulin secretion in islet \u03b2 cells","volume":"18","author":"Tang","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.bioorg.2025.108693_bb0630","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.febslet.2007.11.040","article-title":"PPAR\u03b4 as a therapeutic target in metabolic disease","volume":"582","author":"Reilly","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bioorg.2025.108693_bb0635","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3390\/ijms19071893","article-title":"Insights into the role of PPAR\u03b2\/\u03b4 in NAFLD","volume":"19","author":"Chen","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0640","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000503995","article-title":"Aberrant expression of peroxisome proliferator-activated receptors in colorectal cancer and their association with cancer progression and prognosis","volume":"7","author":"Yaghoubizadeh","year":"2019","journal-title":"Gastrointestinal Tumors"},{"key":"10.1016\/j.bioorg.2025.108693_bb0645","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1096\/fj.14-264515","article-title":"15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6\/STAT3 signaling pathway","volume":"29","author":"Mao","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.bioorg.2025.108693_bb0650","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nature17173","article-title":"High-fat diet enhances stemness and tumorigenicity of intestinal progenitors","volume":"531","author":"Beyaz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108693_bb0655","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91419","article-title":"Metastasis regulation by PPARD expression in cancer cells","volume":"2","author":"Zuo","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.bioorg.2025.108693_bb0660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016215","article-title":"PPAR\u03b4 activation acts cooperatively with 3-phosphoinositide-dependent protein kinase-1 to enhance mammary tumorigenesis","volume":"6","author":"Pollock","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bioorg.2025.108693_bb0665","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.bbrc.2016.08.043","article-title":"Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders","volume":"483","author":"Agarwal","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.108693_bb0670","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbadis.2004.11.011","article-title":"Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes","volume":"1740","author":"Luquet","year":"2005","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.bioorg.2025.108693_bb0675","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/01.ATV.0000250972.83623.61","article-title":"Activation of PPAR\u03b2\/\u03b4 induces endothelial cell proliferation and angiogenesis","volume":"27","author":"Piqueras","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0680","doi-asserted-by":"crossref","first-page":"12890","DOI":"10.1073\/pnas.0705505104","article-title":"Transcriptional network governing the angiogenic switch in human pancreatic cancer","volume":"104","author":"Abdollahi","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0685","doi-asserted-by":"crossref","first-page":"19069","DOI":"10.1073\/pnas.0607948103","article-title":"Crosstalk between peroxisome proliferator-activated receptor \u03b4 and VEGF stimulates cancer progression","volume":"103","author":"Wang","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0690","doi-asserted-by":"crossref","first-page":"33240","DOI":"10.1074\/jbc.M507617200","article-title":"Activation of peroxisome proliferator-activated receptor \u03b2\/\u03b4 (PPAR\u03b2\/\u03b4) increases the expression of prostaglandin E2 receptor subtype EP4: the roles of phosphatidylinositol 3-kinase and CCAAT\/enhancer-binding protein \u03b2","volume":"280","author":"Han","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108693_bb0695","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/carcin\/bgx035","article-title":"PPAR\u03b4 promotes tumor progression via activation of Glut1 and SLC1-A5 transcription","volume":"38","author":"Zhang","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bioorg.2025.108693_bb0700","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/mc.22144","article-title":"PPAR\u03b4 deficiency disrupts hypoxia-mediated tumorigenic potential of colon cancer cells","volume":"53","author":"Jeong","year":"2014","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bioorg.2025.108693_bb0705","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccr.2004.08.011","article-title":"Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor \u03b4","volume":"6","author":"Wang","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2025.108693_bb0710","doi-asserted-by":"crossref","first-page":"7084","DOI":"10.1073\/pnas.1324233111","article-title":"Peroxisome proliferator-activated receptor \u03b4 promotes colonic inflammation and tumor growth","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0715","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/carcin\/bgi221","article-title":"NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)\u03b4 expression in APCmin \/+ mice proportionally to their tumor inhibitory effect: implications for the role of PPAR\u03b4 in carcinogenesis","volume":"27","author":"Ouyang","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bioorg.2025.108693_bb0720","doi-asserted-by":"crossref","first-page":"dju052","DOI":"10.1093\/jnci\/dju052","article-title":"Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-\u03b4\/\u03b2 overexpression","volume":"106","author":"Zuo","year":"2014","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioorg.2025.108693_bb0725","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/jnci\/djp078","article-title":"Targeted genetic disruption of peroxisome proliferator\u2013activated receptor-\u03b4 and colonic tumorigenesis","volume":"101","author":"Zuo","year":"2009","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioorg.2025.108693_bb0730","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/571783","article-title":"Induction of metastatic gastric cancer by peroxisome proliferator-activated receptor\u03b4 activation","volume":"2010","author":"Pollock","year":"2010","journal-title":"PPAR Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0735","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/j.gastro.2011.05.004","article-title":"\u0392-Catenin and p120 mediate PPAR\u03b4-dependent proliferation induced by helicobacter pylori in human and rodent epithelia","volume":"141","author":"Nagy","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2025.108693_bb0740","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/mc.20546","article-title":"Regulation of peroxisome proliferator-activated receptor-\u03b2\/\u03b4 by the APC\/\u03b2-CATENIN pathway and nonsteroidal antiinflammatory drugs","volume":"48","author":"Foreman","year":"2009","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bioorg.2025.108693_bb0745","doi-asserted-by":"crossref","DOI":"10.32527\/2018\/101375","article-title":"PPAR\u03b4, a potential therapeutic target for heart disease","volume":"5","author":"Yang","year":"2018","journal-title":"Nucl. Recept. Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0750","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3390\/ijms19072013","article-title":"PPAR\u03b2\/\u03b4: linking metabolism to regeneration","volume":"19","author":"Magadum","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0770","doi-asserted-by":"crossref","first-page":"15924","DOI":"10.1073\/pnas.0306981100","article-title":"Activation of peroxisome proliferator-activated receptor \u03b4 induces fatty acid \u03b2-oxidation in skeletal muscle and attenuates metabolic syndrome","volume":"100","author":"Tanaka","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.108693_bb0775","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1172\/JCI27955","article-title":"PPAR\u03b4: a dagger in the heart of the metabolic syndrome","volume":"116","author":"Barish","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.108693_bb0780","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/0008-5472.CAN-06-3431","article-title":"Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3\u03b5","volume":"67","author":"Liou","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0785","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1158\/0008-5472.CAN-07-0828","article-title":"Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-\u03b4 signaling in epithelial ovarian cancer","volume":"67","author":"Daikoku","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0790","doi-asserted-by":"crossref","first-page":"8211","DOI":"10.1038\/sj.onc.1208983","article-title":"Both PPAR\u03b3 and PPAR\u03b4 influence sulindac sulfide-mediated p21WAF1\/CIP1 upregulation in a human prostate epithelial cell line","volume":"24","author":"Jarvis","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.108693_bb0795","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/me.2007-0190","article-title":"Identification and characterization of a selective peroxisome proliferator-activated receptor \u03b2\/\u03b4 (NR1C2) antagonist","volume":"22","author":"Shearer","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0800","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1535-7163.MCT-07-2063","article-title":"A small-molecule inhibitor of Tcf\/\u03b2-catenin signaling down-regulates PPAR\u03b3 and PPAR\u03b4 activities","volume":"7","author":"Handeli","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.108693_bb0805","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1684\/ejd.2014.2505","article-title":"Nuclear receptor peroxisome proliferator activated receptor (PPAR) \u03b2\/\u03b4 in skin wound healing and cancer","volume":"25","author":"Montagner","year":"2015","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.bioorg.2025.108693_bb0755","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037097","article-title":"Skin-targeted inhibition of PPAR \u03b2\/\u03b4 by selective antagonists to treat PPAR \u03b2\/\u03b4 \u2013 mediated psoriasis-like skin disease in vivo","volume":"7","author":"Hack","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bioorg.2025.108693_bb0810","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/onc.2012.549","article-title":"Inverse PPAR\u03b2\/\u03b4 agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion","volume":"32","author":"Adhikary","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.108693_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115122","article-title":"Development of a novel class of peroxisome proliferator-activated receptor (PPAR) gamma ligands as an anticancer agent with a unique binding mode based on a non-thiazolidinedione scaffold","volume":"27","author":"Yamamoto","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108693_bb0820","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/25931","article-title":"Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-\u03b3","volume":"395","author":"Nolte","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108693_bb0825","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature07413","article-title":"Structure of the intact PPAR-\u03b3\u2013RXR-\u03b1 nuclear receptor complex on DNA","volume":"456","author":"Chandra","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108693_bb0830","first-page":"3479","article-title":"Enhanced expression of peroxisome proliferate-activated receptor gamma (PPAR-\u03b3) in advanced prostate cancer","volume":"32","author":"Rogenhofer","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bioorg.2025.108693_bb0835","first-page":"598","article-title":"PPAR\u03b3 against Tumors by different Signaling pathways","volume":"36","author":"Zhang","year":"2013","journal-title":"Onkologie"},{"key":"10.1016\/j.bioorg.2025.108693_bb0840","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016179","article-title":"Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPAR\u03b3 independent manner","volume":"6","author":"Al-Alem","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bioorg.2025.108693_bb0845","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa073394","article-title":"Rosiglitazone evaluated for cardiovascular outcomes \u2014 an interim analysis","volume":"357","author":"Home","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108693_bb0850","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/dme.12144","article-title":"Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies","volume":"30","author":"Ferwana","year":"2013","journal-title":"Diabet. Med."},{"key":"10.1016\/j.bioorg.2025.108693_bb0855","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bioorg.2025.108693_bb0860","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.3390\/cancers12092623","article-title":"The role of PPAR\u03b3 ligands in breast cancer: from basic research to clinical studies","volume":"12","author":"Augimeri","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.108693_bb0865","doi-asserted-by":"crossref","first-page":"19649","DOI":"10.1074\/jbc.M200743200","article-title":"T0070907, a selective ligand for peroxisome proliferator-activated receptor \u03b3, functions as an antagonist of biochemical and cellular activities","volume":"277","author":"Lee","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108693_bb0870","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2337\/db15-1382","article-title":"PPAR\u03b3 antagonist gleevec improves insulin sensitivity and promotes the browning of white adipose tissue","volume":"65","author":"Choi","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.bioorg.2025.108693_bb0875","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrc2129","article-title":"Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer","volume":"7","author":"Liby","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108693_bb0880","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPAR\u03b3","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bioorg.2025.108693_bb0885","article-title":"PPAR\u03b3 negatively regulates t cell activation to prevent follicular helper T cells and germinal center formation","volume":"9","author":"Park","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bioorg.2025.108693_bb0890","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-pathol-011110-130138","article-title":"Alternative macrophage activation and metabolism","volume":"6","author":"Odegaard","year":"2011","journal-title":"Annu. Rev. Pathol.: Mech. Dis."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825005735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825005735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:59:50Z","timestamp":1776920390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825005735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":176,"alternative-id":["S0045206825005735"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108693","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peroxisome proliferator-activated receptor antagonists as emerging therapeutics in cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108693"}}